SMARCA4 and prostate cancer: Although specific trials for bone metastatic breast or prostate cancers are currently absent, the expanding array of SWI/SNF-targeting agents, including BRD9 degraders and SMARCA4/2 inhibitors, provides a basis for future translational research in this domain [257].